GH

Guardant Health Expands Guardant360® Portfolio With New Tests for Treatment Response Monitoring and Complete Genomic Profiling

CORRECTING and REPLACING Guardant Health Presents Data at 2021 ASCO Annual Meeting Showing Utility of Liquid Biopsy in Early- and Late-Stage Cancers

Guardant Health: A Stalwart With 20% Upside

Guardant Health Presents Data at 2021 ASCO Annual Meeting Showing Blood Test Highly Accurate in Detecting Colorectal Cancer in Patients With Early-Stage Cancer

Guardant360® CDx Receives FDA Approval as First and Only Liquid Biopsy Companion Diagnostic for Amgen's LUMAKRAS™ (sotorasib) KRASG12C Inhibitor for Use in Advanced Non-Small Cell Lung Cancer

Guardant Health Files Lawsuit Against Natera for Misleading Oncologists

Where Guardant Health Stands With Analysts